Microba Life Sciences Management
Management criteria checks 2/4
Microba Life Sciences' CEO is Luke Reid, appointed in Jul 2021, has a tenure of 5.17 years. total yearly compensation is A$667.93K, comprised of 55.1% salary and 44.9% bonuses, including company stock and options. directly owns 0.071% of the company’s shares, worth A$28.63K. The average tenure of the management team and the board of directors is 1.7 years and 3.8 years respectively.
Key information
Luke Reid
Chief executive officer
AU$667.9k
Total compensation
| CEO salary percentage | 55.10% |
| CEO tenure | 5.2yrs |
| CEO ownership | 0.07% |
| Management average tenure | 1.7yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
MAP: Recent Equity Raising Will Support Future Upside Potential
Analysts have lifted their fair value estimate for Microba Life Sciences from A$0.08 to A$0.12, reflecting updated assumptions around revenue growth, profit margins and a higher future P/E multiple. What’s in the News for Microba Life Sciences Microba Life Sciences completed a follow on equity offering of A$5.000212 million in ordinary shares, including 91,344,455 securities at A$0.05 with a A$0.003 discount per security and attached options, and a further 8,659,785 securities on the same terms, with the transaction described as a subsequent direct listing.MAP: Capital Raising Plans Will Support Future Upside Potential
Analysts have cut their fair value estimate for Microba Life Sciences from A$0.22 to about A$0.08, reflecting updated assumptions around the discount rate, revenue growth, profit margin and future P/E expectations. What’s in the News for Microba Life Sciences Microba Life Sciences has scheduled a Special and Extraordinary Shareholders Meeting for July 24, 2026, at 13:00 E.
MAP: Upcoming Capital Raise Will Support Future Microbiome Commercialisation Plans
Analysts have reduced their price target for Microba Life Sciences from A$0.15 to A$0.12, reflecting updated assumptions around fair value, revenue growth, profit margins, and future P/E expectations. What’s in the News for Microba Life Sciences Microba Life Sciences has scheduled a Special or Extraordinary Shareholders Meeting for July 24, 2026, at Thomsons, Level 28, 1 Eagle Street, Brisbane QLD 4000, Australia.MAP: Upcoming Capital Raise Will Support Future Microbiome Commercialisation Plans
Analysts have reduced their fair value estimate for Microba Life Sciences from A$0.29 to about A$0.15, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E multiples. What's in the News Microba Life Sciences has scheduled a Special or Extraordinary Shareholders Meeting for July 24, 2026, at Thomsons, Level 28, 1 Eagle Street, Brisbane, QLD 4000, Australia.
Microbiome Testing Reliance Will Pressure Margins Yet Partnering Optionality May Still Emerge
Catalysts About Microba Life Sciences Microba Life Sciences provides microbiome based diagnostic testing and develops live biotherapeutic assets aimed at chronic disease. What are the underlying business or industry changes driving this perspective?Why Investors Shouldn't Be Surprised By Microba Life Sciences Limited's (ASX:MAP) 35% Share Price Surge
Microba Life Sciences Limited ( ASX:MAP ) shareholders would be excited to see that the share price has had a great...Microba Life Sciences Limited (ASX:MAP) Not Flying Under The Radar
Microba Life Sciences Limited's ( ASX:MAP ) price-to-sales (or "P/S") ratio of 2.7x may not look like an appealing...Microba Life Sciences Limited's (ASX:MAP) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
To the annoyance of some shareholders, Microba Life Sciences Limited ( ASX:MAP ) shares are down a considerable 26% in...Microba Life Sciences Limited's (ASX:MAP) 31% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
The Microba Life Sciences Limited ( ASX:MAP ) share price has fared very poorly over the last month, falling by a...Some Confidence Is Lacking In Microba Life Sciences Limited (ASX:MAP) As Shares Slide 29%
The Microba Life Sciences Limited ( ASX:MAP ) share price has softened a substantial 29% over the previous 30 days...We're Hopeful That Microba Life Sciences (ASX:MAP) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...We're Not Very Worried About Microba Life Sciences' (ASX:MAP) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is Microba Life Sciences (ASX:MAP) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2026 | AU$668k | AU$368k | -AU$21m |
| Mar 31 2026 | n/a | n/a | -AU$20m |
| Dec 31 2025 | n/a | n/a | -AU$20m |
| Sep 30 2025 | n/a | n/a | -AU$17m |
| Jun 30 2025 | AU$672k | AU$350k | -AU$15m |
| Mar 31 2025 | n/a | n/a | -AU$15m |
| Dec 31 2024 | n/a | n/a | -AU$14m |
| Sep 30 2024 | n/a | n/a | -AU$17m |
| Jun 30 2024 | AU$567k | AU$310k | -AU$20m |
| Mar 31 2024 | n/a | n/a | -AU$19m |
| Dec 31 2023 | n/a | n/a | -AU$18m |
| Sep 30 2023 | n/a | n/a | -AU$16m |
| Jun 30 2023 | AU$382k | AU$278k | -AU$13m |
| Mar 31 2023 | n/a | n/a | -AU$12m |
| Dec 31 2022 | n/a | n/a | -AU$11m |
| Sep 30 2022 | n/a | n/a | -AU$11m |
| Jun 30 2022 | AU$407k | AU$248k | -AU$11m |
| Mar 31 2022 | n/a | n/a | -AU$11m |
| Dec 31 2021 | n/a | n/a | -AU$11m |
| Sep 30 2021 | n/a | n/a | -AU$9m |
| Jun 30 2021 | AU$268k | AU$144k | -AU$8m |
Compensation vs Market: Luke's total compensation ($USD481.88K) is above average for companies of similar size in the Australian market ($USD344.02K).
Compensation vs Earnings: Luke's compensation has been consistent with company performance over the past year.
CEO
Luke Reid
Dr. Luke Reid is Chief Executive Officer of Microba Life Sciences Limited from July 15, 2021. He is an experienced research and technology commercialisation executive. His deep knowledge of the biotechnolo...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 5.2yrs | AU$667.93k | 0.071% A$ 28.6k | |
| Co-Founder & Non-Executive Director | no data | AU$64.00k | 2.22% A$ 891.5k | |
| CFO & Company Secretary | no data | AU$389.73k | 0.074% A$ 29.8k | |
| Co-Founder & Chair of Scientific Advisory Board | no data | no data | no data | |
| Chief Technology Officer | 2.7yrs | no data | no data | |
| Chief Scientific Officer | no data | no data | no data | |
| Head of Laboratory Operations & Laboratory Director | no data | no data | no data | |
| Head of Test Operations | 1.7yrs | no data | no data | |
| Chief Revenue Officer | 1.7yrs | no data | no data | |
| Managing Director of UK | 1.7yrs | no data | no data |
Experienced Management: MAP's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Non-Executive Director | no data | AU$64.00k | 2.22% A$ 891.5k | |
| Co-Founder & Chair of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Chairman | no data | AU$95.00k | 1.09% A$ 437.9k | |
| Independent Non-Executive Deputy Chairman of the Board & Chair of Medical Advisory Board | no data | AU$85.00k | 0.40% A$ 160.6k | |
| Independent Non-Executive Director | 4yrs | AU$61.13k | no data | |
| Independent Non-Executive Director | less than a year | AU$36.54k | no data | |
| Member of Medical Advisory Board | 3.8yrs | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | 3.8yrs | no data | no data |
Experienced Board: MAP's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/09 12:41 |
| End of Day Share Price | 2026/09/09 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Microba Life Sciences Limited is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tara Speranza | Bell Potter |
| Thomas Wakim | Bell Potter |
| Elyse Shapiro | Canaccord Genuity |